|
Age (years)
|
66 (61–72)
|
66 (63–77)
|
|
Male: n (%)
|
12 (40%)
|
17 (71%)
|
|
FEV1 (L)
|
0.97 (0.69–1.2)
|
NA
|
|
FEV1 (%)
|
35% (29.5–53)
|
NA
|
|
PaO2/FiO2 (mmHg)
|
NA
|
131 (100–190)
|
|
SAPS II:
|
36 (32–50)
|
48 (43–62)
|
|
Use of vasopressors: n (%)
|
10 (33%)
|
14 (58%)
|
|
Type of ventilatory support
|
|
IMV: n (%)
|
21 (70%)
|
24 (100%)
|
|
NIV: n (%)
|
9 (30%)
|
NA
|
|
IMV settings before ECCO2R:
|
|
VT (ml/kg PBW)
|
8.0 (7.8–8.1)
|
5.9 (5.5–6.0)
|
|
Applied PEEP (cmH2O)
|
0 (0–0)
|
10 (5–15.5)
|
|
FiO2 (%)
|
35 (30–38)
|
60 (50–70)
|
|
Measured parameters under IMV before ECCO2R:
|
|
Plateau pressure (cmH2O)
|
NA
|
28 (27–29)
|
|
Total PEEP (cmH2O)
|
9 (7–11)
|
NA
|
|
pH
|
7.30 (7.25–7.32)
|
7.24
|
|
PaCO2 (mmHg)
|
67.5 (60.75–73.25)
|
58.0 (48.0–65.0)
|
|
ECCO2R device
|
|
iLa Activve: n (%)
|
5 (17%)
|
6 (25%)
|
|
Hemolung: n (%)
|
25 (83%)
|
18 (75%)
|
|
IMV settings and measured parameters at day 1 after starting ECCO2R:
|
|
VT (ml/kg PBW)
|
7.98 (7.70–8.10)
|
4.1 (3.9–4.8)*
|
|
pH
|
7.39 (7.26–7.42)*
|
7.31 (7.24–7.36)**
|
|
PaCO2 (mmHg)
|
51.0 (45.5–56.0)*
|
51.0 (44.5–55.7)
|
|
ECCO2R duration (days):
|
6.5 (3.25–8)
|
4 (2–6)
|
|
IMV duration (days)
|
10 (4.75–15.25)
|
8.5 (5.5–14.25)
|
|
Course of ventilator support
|
|
IMV weaning success (IMV patients)
|
16 (76%)
|
7 (29%)
|
|
Intubation (NIV patients)
|
1 (11%)
|
NA
|
|
Mortality: n (%)
|
10 (31%)
|
17 (71%)
|
|
Linked to ECCO2R
|
2 (7%)
|
1 (4%)
|
